Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
life sciences
national blog main
san diego blog main
9
×
san diego top stories
boston blog main
boston top stories
clinical trials
fda
national top stories
new york blog main
san francisco blog main
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
bristol-myers squibb
ipo
national
san diego
startups
allergan
boston
cancer
chronic kidney disease
crispr
dyne therapeutics
gene therapy
What
therapeutics
9
×
drug
ipo
medicines
million
new
raised
bio
biotechs
cancer
chief
companies
company
developing
diseases
dyne
genetic
immunotherapy
life
muscle
officer
rare
roundup
science
treat
week
year
abide
agency
ago
aimmune
allergy
allogene
appointed
approval
approved
athena
awarded
bacteria
biopharma
Language
unset
Current search:
therapeutics
×
" san diego blog main "
×
@xconomy.com
3 years ago
Dyne’s Upsized IPO Brings In $233M for Muscle Disorders Drug R&D
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
4 years ago
Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy
@xconomy.com
4 years ago
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More
@xconomy.com
5 years ago
Former Zavante Executive Tapped as Abide Therapeutics President
@xconomy.com
5 years ago
Qpex Biopharma Launches with $33M to Tackle Drug-Resistant Infections
@xconomy.com
5 years ago
TP Therapeutics Names New CEO, Gets $80M More For Cancer Drug Push
@xconomy.com
5 years ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More
@xconomy.com
5 years ago
IPO Wave Rolls On as Five Life Science Firms Haul in $651M